The Nuclear Medicine Radioisotopes Market was valued at USD 6,595.98 million in 2021 and is expected to reach USD 10,984.47 million by 2028, registering a CAGR of 8% during the forecast period 2022-2028.
The increasing incidence of cancer and heart disease is a major driver for the nuclear drug radioisotope market. Nuclear medicine has tremendous potential for the treatment of cancer and heart disease. The growth of medical imaging is an opportunity for the growth of the global nuclear medicine radioisotope market as the two markets are interrelated. Radiopharmaceuticals have been approved by the Food and Drug Administration (FDA) as pharmaceuticals or biologics.
(Get 15% Discount on Buying this Report)
A full report of Global Nuclear Medicine Radioisotopes Market is available at: https://orionmarketreports.com/nuclear-medicine-radioisotopes-market/89675/
Market Segments
By Types
- Thallium-201 (Tl-201)
- Iodine (I-123)
- Fluorine-18
- Rubidium-82 (Rb-82)
By Applications
- Tumor
- Heart Disease
- Lymphoma
- Thyroid Gland
Key Players
GE Company (GE Healthcare), NTP Radioisotopes SOC Ltd, Nordion Inc., (Sotera Health company), Cardinal Health, Inc., Bayer AG, Siemens Healthcare, and Positron Corp. are some of the major players in the nuclear medicine radioisotopes market.
Scope of the Report
The research study analyzes the global Nuclear Medicine Radioisotopes industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:
Recent Developments
o Market Overview and growth analysis
o Import and Export Overview
o Volume Analysis
o Current Market Trends and Future Outlook
o Market Opportunistic and Attractive Investment Segment
Geographic Coverage
o North America Market Size and/or Volume
o Latin America Market Size and/or Volume
o Europe Market Size and/or Volume
o Asia-Pacific Market Size and/or Volume
o Rest of the world Market Size and/or Volume
Key Questions Answered by Nuclear Medicine Radioisotopes Market Report
1. What was the Nuclear Medicine Radioisotopes Market size in 2020 and 2021; what are the estimated growth trends and market forecast (2022-2028).
2. What will be the CAGR of Nuclear Medicine Radioisotopes Market during the forecast period (2022-2028)?
3. Which segments (product type/applications/end-user) were most attractive for investments in 2022? How these segments are expected to grow during the forecast period (2022-2028).
4. Which manufacturer/vendor/players in the Nuclear Medicine Radioisotopes Market was the market leader in 2020?
5. Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.
The report covers the following objectives:
- Proliferation and maturation of trade in the global Nuclear Medicine Radioisotopes market.
- The market share of the global Nuclear Medicine Radioisotopes market, supply and demand ratio, growth revenue, supply chain analysis, and business overview.
- Current and future market trends that are influencing the growth opportunities and growth rate of the global Nuclear Medicine Radioisotopes market.
- Feasibility study, new market insights, company profiles, investment return, revenue (value), and consumption (volume) of the global Nuclear Medicine Radioisotopes market.
About Us:
Orion Market Reports (OMR) endeavors to provide an exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and the most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
